No annual revenue total was found in Jade Biosciences, Inc.'s SEC filings.
Jade Biosciences, Inc. (JBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$94.9 million. As of Jun 30, 2026 it held $461.2 million in cash and investments and $761,000 in total debt.
Revenue
—
Net income (TTM)
$-153.24M
-66.6% vs year-ago TTM
Operating cash flow (TTM)
$-123.51M
-87.1% vs year-ago TTM
Free cash flow
$-94.89M
-66.7% vs prior year
EPS (TTM)
$-2.90
+29.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
49.32M
+70.1% vs prior year
Net cash
$460.44M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1798749
- Former names
- Aerovate Therapeutics, Inc. (until Apr 30, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$113.5M | -$74.6M | -$81.4M | -$53.2M | -$23.0M |
| Net income | -$127.4M | -$69.6M | -$75.5M | -$51.5M | -$23.0M |
| Diluted EPS | -$3.19 | -$2.44 | -$2.87 | -$2.10 | — |
| Operating cash flow | -$94.7M | -$71.2M | -$56.8M | -$39.1M | -$27.4M |
| Free cash flow | -$94.9M | — | -$56.9M | -$39.3M | -$27.6M |
| Total assets | $349.8M | $72.8M | $127.4M | $135.3M | $175.4M |
| Total liabilities | $17.3M | $119.6M | $18.0M | $8.6M | $2.9M |
| Stockholders' equity | $332.5M | -$46.8M | $109.5M | $126.7M | $172.4M |
| Cash and investments | $336.2M | $69.4M | $122.4M | $129.2M | $167.4M |
| Total debt | $851,000 | $417,000 | $675,000 | $1.1M | $574,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 1, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 26, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 11, 2026 | Jun 8, 2026 |
All 509 Jade Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.